TYRA

Tyra Biosciences Inc

21.11

Nov 02 • 1:47 PM ET +0.04 (0.18%)

Healthcare Biotechnology USA Small NASD

Peers: BBIO BMRN ASND RLAY URGN CGON INCY ELVN TNGX JNJ

| Held by: VTI XBI IWM VXF IBB IWO SCHA VTWO DFAS VHT

Index	RUT
Market Cap	1.45B
Enterprise Value	1.10B
Income	-148.56M
Sales	0.00M
Book/sh	5.93
Cash/sh	5.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	87
IPO	Sep 15, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.56
P/C	4.10
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	14.91
Current Ratio	14.91
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.39
EPS next Y	-2.80
EPS next Q	-0.67
EPS this Y	-31.94%
EPS next Y	-5.58%
EPS next 5Y	-16.83%
EPS past 3/5Y	-15.07% -55.76%
Sales past 3/5Y	- -
EPS Y/Y TTM	-33.90%
Sales Y/Y TTM	-
EPS Q/Q	-46.33%
Sales Q/Q	-
Earnings	Aug 04 AMC
EPS/Sales Surpr.	-6.17% -

Insider Own	23.30%
Insider Trans	0.01%
Inst Own	96.61%
Inst Trans	6.75%
ROA	-42.15%
ROE	-45.31%
ROIC	-41.41%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.48%
SMA50	-6.50%
SMA200	-29.25%
Trades

Shs Outstand	59.66M
Shs Float	45.77M
Short Float	20.75%
Short Ratio	10.94
Short Interest	9.50M
52W High	40.65 -48.08%
52W Low	13.35 58.10%
Volatility	5.22% 4.83%
ATR (14)	1.12
RSI (14)	49.23
Beta	0.65
Rel Volume	0.43
Avg Volume	867.79K
Volume	251,267

Perf Week	3.36%
Perf Month	3.31%
Perf Quarter	-35.12%
Perf Half Y	-39.93%
Perf YTD	-19.72%
Perf Year	33.25%
Perf 3Y	65.54%
Perf 5Y	-12.60%
Perf 10Y	-
Recom	1.20
Target Price	47.45
Prev Close	21.07
Price	21.11
Change %	0.18%

Consensus

Strong Buy

Avg. Price Target

$47.45

Implied Upside

+124.8%

Analysts15incl. previous ratings

Rating Distribution14 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 19, 2026	Initiated	WWolfe Research	Peer Perform
Apr 15, 2026	Initiated	GGuggenheim	Buy	$54	+155.8%
Apr 06, 2026	Initiated	CCanaccord Genuity	Buy	$50	+136.9%
Feb 24, 2026	Initiated	CCantor Fitzgerald	Overweight
Feb 10, 2026	Initiated	WWilliam Blair	Outperform
Jan 28, 2026	Initiated	BBarclays	Overweight	$59	+179.5%
Sep 03, 2025	Initiated	RRaymond James	Strong Buy	$35	+65.8%
May 21, 2025	Resumed	PPiper Sandler	Overweight	$33	+56.3%
Jan 07, 2025	Initiated	UUBS	Buy	$28	+32.7%
Oct 18, 2024	Upgrade	BBofA Securities	Neutral → Buy	$22 → $31	+46.9%
Aug 15, 2024	Initiated	PPiper Sandler	Overweight	$33	+56.3%
Dec 15, 2023	Downgrade	BBofA Securities	Buy → Neutral	$25 → $15	-28.9%
Jun 30, 2023	Initiated	WWedbush	Outperform	$27	+27.9%
Feb 03, 2023	Initiated	OOppenheimer	Outperform	$17	-19.5%
Jun 23, 2022	Initiated	HH.C. Wainwright	Buy	$12	-43.1%
Mar 08, 2022	Upgrade	JJefferies	Hold → Buy	$31 → $27	+27.9%
Nov 08, 2021	Downgrade	JJefferies	Buy → Hold
Oct 11, 2021	Initiated	JJefferies	Buy	$19	-10.0%
Oct 11, 2021	Initiated	CCowen	Outperform
Oct 11, 2021	Initiated	BBofA Securities	Buy	$22	+4.2%

Oct-01-26 04:26PM	Raymond James Updates Healthcare Top Picks for October (Investing.com)
Sep-14-26 06:45AM	Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +13.80%
Sep-09-26 11:46AM	Tyra disappoints investors with bladder cancer data (BioPharma Dive) -17.66%
10:44AM	Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress (Barrons.com)
10:05AM	Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data (InvestorsHub)
07:00AM	Loading…
07:00AM	Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib (PR Newswire)
Sep-08-26 04:05PM	Tyra Biosciences to Present at the Cantor Global Healthcare Conference (PR Newswire) -6.70%
Sep-04-26 02:25PM	TYRA Stock Heads For Best Day In Nearly 10 Months Sets Date For Key Phase 2 Bladder Cancer Drug Readout (Stocktwits) +15.25%
08:00AM	Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 (PR Newswire)
Aug-04-26 04:05PM	Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights (PR Newswire) -20.97%
May-21-26 08:00AM	TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY (PR Newswire)
May-13-26 08:00AM	Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights (PR Newswire)
May-07-26 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Apr-17-26 08:00AM	Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors (PR Newswire)
Mar-02-26 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights (PR Newswire)
02:11AM	Loading…
02:11AM	Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data (MarketBeat)
Feb-23-26 05:30PM	Tyra Biosciences Announces Poster Presentations at the 2026 ASCO Genitourinary (GU) Cancers Symposium (PR Newswire) +5.45%
Feb-19-26 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire) +6.56%
Feb-14-26 09:05AM	Tyra Biosciences price target raised to $53 from $37 at Wedbush (TipRanks)
Dec-01-25 08:00AM	Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer (PR Newswire) -7.76%
Nov-12-25 04:05PM	Tyra Biosciences Announces Participation at Upcoming Investor Events (PR Newswire)
Nov-05-25 04:05PM	Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights (PR Newswire)
Aug-22-25 05:38AM	Tyra Biosciences initiates paediatric study for achondroplasia treatment (Clinical Trials Arena)
Aug-21-25 08:00AM	Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia (PR Newswire) +14.26%
Aug-20-25 04:05PM	Tyra Biosciences Announces Participation at Upcoming Investor Events (PR Newswire)
Aug-19-25 09:55AM	Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks) -5.64%
Aug-14-25 04:05PM	Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights (PR Newswire)
Jul-21-25 04:05PM	Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series (PR Newswire)
Jul-08-25 04:05PM	Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 (PR Newswire)
Jun-30-25 08:00AM	Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) (PR Newswire) +5.16%
04:05PM	Loading…
May-12-25 04:05PM	Tyra Biosciences to Participate at Upcoming Investor Conferences (PR Newswire)
May-08-25 04:05PM	Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights (PR Newswire) +10.30%
Mar-27-25 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights (PR Newswire) -5.66%
Feb-11-25 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Jan-29-25 04:05PM	Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors (PR Newswire)
Jan-22-25 08:00AM	Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-10-25 08:00AM	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) (PR Newswire)
Nov-13-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-07-24 04:05PM	Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights (PR Newswire) -6.06%
Oct-28-24 07:00AM	Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) (PR Newswire) -9.30%
Oct-24-24 06:05PM	Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) (PR Newswire) -23.35%
Oct-23-24 04:05PM	Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET (PR Newswire)
Oct-22-24 09:07PM	RA Capital Management, L.P. Reduces Stake in Tyra Biosciences Inc (GuruFocus.com)
Oct-18-24 02:34PM	BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug (Benzinga) +5.20%
Oct-16-24 01:01AM	Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc (GuruFocus.com) +5.89%
Oct-11-24 08:00AM	Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) (PR Newswire)
Sep-11-24 04:05PM	Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference (PR Newswire) -5.22%
Sep-10-24 04:05PM	Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer (PR Newswire)
Sep-09-24 09:55AM	Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet (Zacks)
Aug-27-24 07:50PM	Tyra Biosciences, Inc. (TYRA): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 11:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights (PR Newswire)
Jul-02-24 04:05PM	Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) (PR Newswire)
Jun-07-24 12:00PM	Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High? (Zacks)
May-23-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
May-09-24 10:54PM	TYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights (PR Newswire)
May-07-24 04:05PM	Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors (PR Newswire)
Mar-19-24 09:53PM	TYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023 (InvestorPlace) +7.89%
09:01PM	Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress (GuruFocus.com)
04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights (PR Newswire)
Mar-05-24 11:27PM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares (GuruFocus.com)
Mar-01-24 12:40AM	Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Shares (GuruFocus.com)
Feb-27-24 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Feb-07-24 04:05PM	Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference (PR Newswire)
03:12AM	President and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA) (GuruFocus.com)
Feb-02-24 08:00AM	Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing (PR Newswire) +29.29%
Feb-01-24 05:30PM	Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-22-23 09:00AM	Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 (PR Newswire)
Nov-08-23 04:05PM	Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference (PR Newswire)
Nov-07-23 04:05PM	Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights (PR Newswire) -5.00%
Sep-21-23 08:00AM	Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings (PR Newswire)
Sep-12-23 04:05PM	Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference (PR Newswire)
Aug-10-23 04:05PM	Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights (PR Newswire)
Aug-01-23 08:00AM	Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia (PR Newswire)
Jun-16-23 08:50AM	Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength (Zacks) +6.25%
Jun-07-23 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet (Zacks) -5.63%
May-25-23 08:00AM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
May-23-23 08:50AM	What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing' (Zacks)
May-22-23 09:55AM	Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade (Zacks)
Apr-09-23 09:30AM	Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation (Simply Wall St.)
Mar-29-23 04:05PM	Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Mar-27-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA) (Zacks)
Mar-22-23 04:05PM	Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights (PR Newswire) -5.01%
Mar-01-23 08:40AM	Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings? (Zacks)
07:00AM	Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia (PR Newswire)
Feb-22-23 04:05PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire) -7.99% -9.04%
Nov-29-22 07:00AM	Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300 (PR Newswire)
Nov-24-22 09:55AM	How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184% (Zacks)
Nov-10-22 04:20PM	Tyra Biosciences to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 09:55AM	Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet (Zacks)
Nov-03-22 04:05PM	Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights (PR Newswire) -7.00%
Nov-02-22 04:05PM	Tyra Biosciences Announces Planned Chief Financial Officer Transition (PR Newswire)
Oct-31-22 09:22AM	We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth (Simply Wall St.)
Oct-13-22 08:00AM	Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.46%
Sep-08-22 04:05PM	Tyra Biosciences to Participate at September 2022 Investor Conferences (PR Newswire) +8.24%
Sep-05-22 08:15AM	Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress (PR Newswire)
Aug-04-22 04:05PM	Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights (PR Newswire) +14.97%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Verjee Rehan	Director	Sep 09 '26	Buy	20.58	972	20,000	972	Sep 11 04:30 PM
NEXTECH VI ONCOLOGY SCSP	Shareholder	Jun 26 '26	Proposed Sale	30.94	308,379	9,541,246		Jun 26 04:59 PM
NEXTECH VI ONCOLOGY SCSP	Shareholder	Jun 01 '26	Proposed Sale	33.41	300,000	10,023,000		Jun 01 04:16 PM
Daniel Bensen	Officer	May 12 '26	Proposed Sale	34.25	8,000	274,000		May 12 05:33 PM
Daniel Bensen	Officer	Apr 13 '26	Proposed Sale	35.62	8,000	285,000		Apr 13 04:44 PM
KAPLAN GILLA	Director	Mar 25 '26	Option Exercise	2.25	14,295	32,164	42,526	Mar 27 04:44 PM
KAPLAN GILLA	Director	Mar 25 '26	Sale	36.97	14,295	528,506	28,231	Mar 27 04:44 PM
GILLA KAPLAN	Director	Mar 26 '26	Proposed Sale	37.75	53,172	2,007,153		Mar 26 04:04 PM
GILLA KAPLAN	Director	Mar 25 '26	Proposed Sale	36.97	14,295	528,506		Mar 25 05:36 PM
Daniel Bensen	Officer	Mar 12 '26	Proposed Sale	35.38	8,000	283,000		Mar 12 05:42 PM
Bensen Daniel	Chief Discovery Officer	Feb 12 '26	Sale	32.87	8,000	262,965	146,981	Feb 13 04:30 PM
Daniel Bensen	Officer	Feb 12 '26	Proposed Sale	32.75	8,000	262,000		Feb 12 04:52 PM
Bensen Daniel	Chief Discovery Officer	Jan 12 '26	Sale	28.52	8,000	228,186	154,981	Jan 20 04:30 PM
Daniel Bensen	Officer	Jan 12 '26	Proposed Sale	29.00	8,000	232,000		Jan 12 05:38 PM
MORE ROBERT J	Director	Dec 19 '25	Sale	25.00	10,000	250,000	3,823,425	Dec 19 09:00 PM
Bensen Daniel	Chief Discovery Officer	Dec 12 '25	Sale	22.64	8,000	181,159	162,981	Dec 16 04:30 PM
Daniel Bensen	Officer	Dec 12 '25	Proposed Sale	22.50	8,000	180,000		Dec 12 04:21 PM
MORE ROBERT J	Director	Nov 21 '25	Sale	20.25	246,871	5,000,026	3,833,425	Nov 25 05:00 PM
Alta Partners NextGen Fund II,	Affiliate	Nov 21 '25	Proposed Sale	21.00	256,871	5,394,291		Nov 21 04:26 PM
Bensen Daniel	Chief Operating Officer	Nov 18 '25	Sale	16.07	75,633	1,215,627	220,937	Nov 19 07:30 PM
Bensen Daniel	Chief Operating Officer	Nov 19 '25	Sale	16.32	49,956	815,297	170,981	Nov 19 07:30 PM
Daniel Bensen	Officer	Nov 18 '25	Proposed Sale	16.05	124,589	2,000,000		Nov 18 05:04 PM
Bensen Daniel	Chief Operating Officer	Nov 14 '25	Sale	16.02	110,228	1,765,489	316,642	Nov 17 07:03 PM
Bensen Daniel	Chief Operating Officer	Nov 17 '25	Sale	16.18	20,072	324,798	296,570	Nov 17 07:03 PM
Bensen Daniel	Chief Operating Officer	Nov 13 '25	Sale	16.00	1,111	17,780	426,870	Nov 17 07:03 PM
Daniel Bensen	Officer	Nov 17 '25	Proposed Sale	15.94	20,072	320,000		Nov 17 04:28 PM
Daniel Bensen	Officer	Nov 14 '25	Proposed Sale	15.98	86,339	1,380,000		Nov 14 04:29 PM
Daniel Bensen	Officer	Nov 13 '25	Proposed Sale	16.00	25,000	400,000		Nov 13 05:40 PM

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Co-FounderDr. Todd Harris Ph.D.

Chief Operating OfficerMr. Bhavesh Ashar M.B.A.

Chief Medical OfficerDr. Douglas Warner M.D.

Co-Founder & Chief Discovery OfficerMr. Daniel Bensen

Chief Financial OfficerMr. Alan Fuhrman CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TYRA

Tyra Biosciences Inc

Upgrade your Finviz experience